echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Targeting CLDN 18.2!

    Targeting CLDN 18.2!

    • Last Update: 2022-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    On November 22, Keji Pharmaceuticals announced that CT041, an autologous CAR-T candidate product that targets CLDN18.


    CT041 is a potential "first-in-class" autologous CAR-T cell candidate product that targets CLDN18.


    Prior to this, CT041 has been approved for clinical studies in China and the United States


    The latest data from the investigator-initiated trial announced at the European Society of Medical Oncology (ESMO) in 2021 shows that CT041 has failed to receive at least 2 lines of therapy in the past, and received the Phase II recommended dose (RP2D) 2.


    According to the press release, Keji Pharmaceutical has applied to the State Food and Drug Administration of China to initiate a key phase 2 clinical trial, and plans to initiate a key phase 2 clinical trial in North America in 2022


    Reference materials:

    [1] The Canadian clinical trial of CT041, a CAR-T product independently developed by Keji Pharmaceuticals, was approved.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.